HEADER HYDROLASE/HYDROLASE INHIBITOR 22-NOV-11 3URI TITLE ENDOTHIAPEPSIN-DB5 COMPLEX. COMPND MOL_ID: 1; COMPND 2 MOLECULE: ENDOTHIAPEPSIN; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: ASPARTATE PROTEASE; COMPND 5 EC: 3.4.23.22; COMPND 6 MOL_ID: 2; COMPND 7 MOLECULE: DB5 PEPTIDE; COMPND 8 CHAIN: B; COMPND 9 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: CRYPHONECTRIA PARASITICA; SOURCE 3 ORGANISM_COMMON: CHESNUT BLIGHT FUNGUS; SOURCE 4 ORGANISM_TAXID: 5116; SOURCE 5 MOL_ID: 2; SOURCE 6 SYNTHETIC: YES KEYWDS HYDROLASE-HYDROLASE INHIBITOR COMPLEX, ASPARTIC PROTEINASE MECHANISM, KEYWDS 2 TRANSITION STATE ANALOGUE. EXPDTA X-RAY DIFFRACTION AUTHOR D.BAILEY,J.SANZ-APARICIO,A.ALBERT,J.B.COOPER REVDAT 7 15-NOV-23 3URI 1 LINK ATOM REVDAT 6 18-APR-18 3URI 1 REMARK REVDAT 5 08-NOV-17 3URI 1 REMARK REVDAT 4 16-DEC-15 3URI 1 ATOM HET SITE REVDAT 3 09-MAY-12 3URI 1 JRNL REVDAT 2 25-APR-12 3URI 1 JRNL REVDAT 1 18-APR-12 3URI 0 JRNL AUTH D.BAILEY,E.P.CARPENTER,A.COKER,S.COKER,J.READ,A.T.JONES, JRNL AUTH 2 P.ERSKINE,C.F.AGUILAR,M.BADASSO,L.TOLDO,F.RIPPMANN, JRNL AUTH 3 J.SANZ-APARICIO,A.ALBERT,T.L.BLUNDELL,N.B.ROBERTS,S.P.WOOD, JRNL AUTH 4 J.B.COOPER JRNL TITL AN ANALYSIS OF SUBDOMAIN ORIENTATION, CONFORMATIONAL CHANGE JRNL TITL 2 AND DISORDER IN RELATION TO CRYSTAL PACKING OF ASPARTIC JRNL TITL 3 PROTEINASES. JRNL REF ACTA CRYSTALLOGR.,SECT.D V. 68 541 2012 JRNL REFN ISSN 0907-4449 JRNL PMID 22525752 JRNL DOI 10.1107/S0907444912004817 REMARK 2 REMARK 2 RESOLUTION. 2.10 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.10 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 10.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : NULL REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.149 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.149 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.253 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 482 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 10301 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : NULL REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : NULL REMARK 3 FREE R VALUE (F>4SIG(F)) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2453 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 289 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : NULL REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : NULL REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : NULL REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : NULL REMARK 3 NUMBER OF RESTRAINTS : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 ANGLE DISTANCES (A) : 0.022 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : NULL REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : NULL REMARK 3 ZERO CHIRAL VOLUMES (A**3) : NULL REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : NULL REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : NULL REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : NULL REMARK 3 SIMILAR ADP COMPONENTS (A**2) : NULL REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: NULL REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH & HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: AUTHOR STATES THAT THE DATA ARE ONLY REMARK 3 ABOUT 60% COMPLETE AS IT IS A VERY OLD DATASET THAT WAS REMARK 3 COLLECTED ON A DIFFRACTOMETER AND THE CRYSTAL DIED BEFORE THE REMARK 3 DATA COLLECTION WAS COMPLETED REMARK 4 REMARK 4 3URI COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 23-NOV-11. REMARK 100 THE DEPOSITION ID IS D_1000069118. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 01-JAN-91 REMARK 200 TEMPERATURE (KELVIN) : 298 REMARK 200 PH : 4.5 REMARK 200 NUMBER OF CRYSTALS USED : 2 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : SEALED TUBE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : OTHER REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.54178 REMARK 200 MONOCHROMATOR : GRAPHITE REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : DIFFRACTOMETER REMARK 200 DETECTOR MANUFACTURER : ENRAF-NONIUS CAD4 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : CADRAL REMARK 200 DATA SCALING SOFTWARE : ROTAVATA AGROVATA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 10301 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.100 REMARK 200 RESOLUTION RANGE LOW (A) : 10.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 60.0 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : 0.15000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: FOURIER SYNTHESIS REMARK 200 SOFTWARE USED: FFT REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 38.11 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.99 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.1M ACETATE BUFFER. 10-FOLD MOLAR REMARK 280 EXCESS OF INHIBITOR DB5 OVER ENZYME. ENZYME CONCENTRATION 2 MG/ REMARK 280 ML. 2.2M AMMONIUM SULPHATE. , PH 4.5, BATCH METHOD, TEMPERATURE REMARK 280 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 37.78000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1420 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 12870 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -11.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 REMARK 400 THE DB5 PEPTIDE IS PEPTIDE-LIKE, A MEMBER OF ENZYME INHIBITOR CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: DB5 PEPTIDE REMARK 400 CHAIN: B REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: NULL REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 HIS B 400 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 HIS B 402 NE2 HIS B 402 CD2 -0.074 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 SUI A 54 CA - C - N ANGL. DEV. = -41.4 DEGREES REMARK 500 13E B 405 CA - C - N ANGL. DEV. = 23.5 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 TRP A 194 80.06 -63.48 REMARK 500 TYR A 234 -71.70 -61.24 REMARK 500 HIS B 402 114.18 176.16 REMARK 500 13E B 405 -172.85 -48.96 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 13E B 405 ALA B 407 -105.24 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: MAIN CHAIN PLANARITY REMARK 500 REMARK 500 THE FOLLOWING RESIDUES HAVE A PSEUDO PLANARITY REMARK 500 TORSION ANGLE, C(I) - CA(I) - N(I+1) - O(I), GREATER REMARK 500 10.0 DEGREES. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 500 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 500 I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI ANGLE REMARK 500 SUI A 54 12.87 REMARK 500 13E B 405 46.05 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 3URJ RELATED DB: PDB REMARK 900 RELATED ID: 3URL RELATED DB: PDB REMARK 999 REMARK 999 ASP A54 AND GLY A55 HAVE CYCLIZED TO FORM A SUCCINIMIDE, SUI A54. DBREF 3URI A 1 329 UNP P11838 CARP_CRYPA 90 419 DBREF 3URI B 401 408 PDB 3URI 3URI 401 408 SEQADV 3URI SUI A 54 UNP P11838 ASP 143 SEE REMARK 999 SEQADV 3URI SUI A 54 UNP P11838 GLY 144 SEE REMARK 999 SEQRES 1 A 329 SER THR GLY SER ALA THR THR THR PRO ILE ASP SER LEU SEQRES 2 A 329 ASP ASP ALA TYR ILE THR PRO VAL GLN ILE GLY THR PRO SEQRES 3 A 329 ALA GLN THR LEU ASN LEU ASP PHE ASP THR GLY SER SER SEQRES 4 A 329 ASP LEU TRP VAL PHE SER SER GLU THR THR ALA SER GLU SEQRES 5 A 329 VAL SUI GLN THR ILE TYR THR PRO SER LYS SER THR THR SEQRES 6 A 329 ALA LYS LEU LEU SER GLY ALA THR TRP SER ILE SER TYR SEQRES 7 A 329 GLY ASP GLY SER SER SER SER GLY ASP VAL TYR THR ASP SEQRES 8 A 329 THR VAL SER VAL GLY GLY LEU THR VAL THR GLY GLN ALA SEQRES 9 A 329 VAL GLU SER ALA LYS LYS VAL SER SER SER PHE THR GLU SEQRES 10 A 329 ASP SER THR ILE ASP GLY LEU LEU GLY LEU ALA PHE SER SEQRES 11 A 329 THR LEU ASN THR VAL SER PRO THR GLN GLN LYS THR PHE SEQRES 12 A 329 PHE ASP ASN ALA LYS ALA SER LEU ASP SER PRO VAL PHE SEQRES 13 A 329 THR ALA ASP LEU GLY TYR HIS ALA PRO GLY THR TYR ASN SEQRES 14 A 329 PHE GLY PHE ILE ASP THR THR ALA TYR THR GLY SER ILE SEQRES 15 A 329 THR TYR THR ALA VAL SER THR LYS GLN GLY PHE TRP GLU SEQRES 16 A 329 TRP THR SER THR GLY TYR ALA VAL GLY SER GLY THR PHE SEQRES 17 A 329 LYS SER THR SER ILE ASP GLY ILE ALA ASP THR GLY THR SEQRES 18 A 329 THR LEU LEU TYR LEU PRO ALA THR VAL VAL SER ALA TYR SEQRES 19 A 329 TRP ALA GLN VAL SER GLY ALA LYS SER SER SER SER VAL SEQRES 20 A 329 GLY GLY TYR VAL PHE PRO CYS SER ALA THR LEU PRO SER SEQRES 21 A 329 PHE THR PHE GLY VAL GLY SER ALA ARG ILE VAL ILE PRO SEQRES 22 A 329 GLY ASP TYR ILE ASP PHE GLY PRO ILE SER THR GLY SER SEQRES 23 A 329 SER SER CYS PHE GLY GLY ILE GLN SER SER ALA GLY ILE SEQRES 24 A 329 GLY ILE ASN ILE PHE GLY ASP VAL ALA LEU LYS ALA ALA SEQRES 25 A 329 PHE VAL VAL PHE ASN GLY ALA THR THR PRO THR LEU GLY SEQRES 26 A 329 PHE ALA SER LYS SEQRES 1 B 8 HIS PRO HIS LEU SER 13E ALA HIS MODRES 3URI SUI A 54 ASP MODRES 3URI SUI A 54 GLY HET SUI A 54 11 HET 13E B 405 18 HETNAM SUI (3-AMINO-2,5-DIOXO-1-PYRROLIDINYL)ACETIC ACID HETNAM 13E N-[(2S)-2-AMINO-3-PHENYLPROPYL]-L-METHIONINE FORMUL 1 SUI C6 H8 N2 O4 FORMUL 2 13E C14 H22 N2 O2 S FORMUL 3 HOH *289(H2 O) HELIX 1 1 THR A 49 VAL A 53 5 5 HELIX 2 2 THR A 59 SER A 63 5 5 HELIX 3 3 SER A 112 ASP A 118 1 7 HELIX 4 4 PHE A 129 ASN A 133 5 5 HELIX 5 5 THR A 142 LYS A 148 1 7 HELIX 6 6 ALA A 149 LEU A 151 5 3 HELIX 7 7 ASP A 174 TYR A 178 5 5 HELIX 8 8 PRO A 227 ALA A 236 1 10 HELIX 9 9 PRO A 273 ILE A 277 1 5 HELIX 10 10 GLY A 305 LYS A 310 1 6 SHEET 1 A 9 LYS A 67 SER A 77 0 SHEET 2 A 9 SER A 83 VAL A 95 -1 O SER A 84 N ILE A 76 SHEET 3 A 9 TYR A 17 ILE A 23 -1 N GLN A 22 O SER A 94 SHEET 4 A 9 GLY A 3 PRO A 9 -1 N THR A 8 O ILE A 18 SHEET 5 A 9 GLY A 166 PHE A 170 -1 O PHE A 170 N GLY A 3 SHEET 6 A 9 VAL A 155 ASP A 159 -1 N ASP A 159 O THR A 167 SHEET 7 A 9 ALA A 312 ASN A 317 -1 O PHE A 316 N PHE A 156 SHEET 8 A 9 THR A 323 SER A 328 -1 O ALA A 327 N PHE A 313 SHEET 9 A 9 THR A 179 ALA A 186 -1 N THR A 179 O SER A 328 SHEET 1 B13 LYS A 67 SER A 77 0 SHEET 2 B13 SER A 83 VAL A 95 -1 O SER A 84 N ILE A 76 SHEET 3 B13 LEU A 98 VAL A 111 -1 O VAL A 105 N TYR A 89 SHEET 4 B13 TRP A 42 PHE A 44 1 N VAL A 43 O GLU A 106 SHEET 5 B13 GLY A 123 GLY A 126 -1 O LEU A 124 N TRP A 42 SHEET 6 B13 GLN A 28 ASP A 35 1 N ASP A 35 O LEU A 125 SHEET 7 B13 TYR A 17 ILE A 23 -1 N ILE A 23 O GLN A 28 SHEET 8 B13 GLY A 3 PRO A 9 -1 N THR A 8 O ILE A 18 SHEET 9 B13 GLY A 166 PHE A 170 -1 O PHE A 170 N GLY A 3 SHEET 10 B13 VAL A 155 ASP A 159 -1 N ASP A 159 O THR A 167 SHEET 11 B13 ALA A 312 ASN A 317 -1 O PHE A 316 N PHE A 156 SHEET 12 B13 THR A 323 SER A 328 -1 O ALA A 327 N PHE A 313 SHEET 13 B13 THR A 179 ALA A 186 -1 N THR A 179 O SER A 328 SHEET 1 C 7 ALA A 268 ILE A 272 0 SHEET 2 C 7 PHE A 261 VAL A 265 -1 N PHE A 263 O ILE A 270 SHEET 3 C 7 GLU A 195 VAL A 203 -1 N GLY A 200 O GLY A 264 SHEET 4 C 7 LYS A 209 ALA A 217 -1 O ILE A 213 N SER A 198 SHEET 5 C 7 ASN A 302 PHE A 304 1 O PHE A 304 N ILE A 216 SHEET 6 C 7 LEU A 224 LEU A 226 -1 N TYR A 225 O ILE A 303 SHEET 7 C 7 ILE A 293 SER A 295 1 O GLN A 294 N LEU A 224 SHEET 1 D 4 LYS A 242 SER A 244 0 SHEET 2 D 4 GLY A 249 PRO A 253 -1 O VAL A 251 N LYS A 242 SHEET 3 D 4 SER A 288 GLY A 291 -1 O CYS A 289 N PHE A 252 SHEET 4 D 4 ASP A 278 PRO A 281 -1 N GLY A 280 O PHE A 290 SSBOND 1 CYS A 254 CYS A 289 1555 1555 2.03 LINK C SUI A 54 N GLN A 55 1555 1555 1.34 LINK C 13E B 405 N ALA B 407 1555 1555 1.33 CISPEP 1 THR A 25 PRO A 26 0 -4.19 CISPEP 2 SER A 136 PRO A 137 0 7.03 CRYST1 43.020 75.560 42.800 90.00 97.02 90.00 P 1 21 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.023245 0.000000 0.002862 0.00000 SCALE2 0.000000 0.013235 0.000000 0.00000 SCALE3 0.000000 0.000000 0.023541 0.00000